Drug intelligence / Profile preview

AlloGen-LI

Development stage: Phase 1
Lead developer: AlloSource
Modality: Cell Therapies
Administration: Epidural

Overview

AlloGen-LI is an allograft derived from human amniotic fluid, developed for its anti-inflammatory and regenerative properties. It is primarily investigated for the treatment of spinal stenosis and disc herniation symptoms, where it is administered via epidural injection to reduce inflammation and alleviate back and leg pain. The product contains a complex mixture of cytokines, growth factors, and other bioactive molecules naturally present in amniotic fluid that modulate the inflammatory response and potentially support tissue repair. As a liquid allograft, it is processed to preserve the natural biological components of the amniotic environment while ensuring safety for clinical use.

Brand names: AlloGen-LI
Other names: Amniotic fluid allograft

Beyond the preview

Go deeper on AlloGen-LI.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AlloGen-LI.

Explore the full profile